The safety and efficacy of remimazolam anesthesia campared with propofol during endobronchial ultrasound-guided transbronchial needle aspiration:A ?prospective randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000040041

Enrollment

Unknown

Registered

2020-11-19

Start date

2020-11-10

Completion date

Unknown

Last updated

2022-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

propofol group:injection propofol 40 mg/kg/h

remimazolam group:injection remimazolam 6 mg/kg/h

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Scheduled for endobronchial ultrasound-guided transbronchial needle aspiration; 2.Aged 18-65 years; 3.With American Society of Anesthesiologists (ASA) physical status I or II; 4.With Mallampati classification I or II.

Exclusion criteria

Exclusion criteria: 1.With circulation dysfunction,liver dysfunction,kidney dysfunction and other important organ dysfunction; 2.Allergic to propofol orBenzodiazepines; 3.A history of drug abuse; 4.With acute upper respiratory infection; 5.With Obstructive sleep apnea hypopnea syndrome or body mass index, BMI >= 28kg/m2.

Design outcomes

Primary

Measure	Time frame
Blood pressure;Heart rate;Oxygenation;Incidence of hypotension;Incidence of bradycardia;	—

Secondary

Measure	Time frame
Surgical completion rate;Induction time;recovery time;Incidence of injection pain;Incidence of postoperative nausea and vomiting;Patients' and physicians' satisfaction of sedation;	—

Countries

China

Contacts

Public ContactLuo Huirong

Fujian Medical University Union Hospital

470797962@qq.com+86 17706918361

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026